CSL Net Income 2017-2021 | CSLLY

CSL annual/quarterly net income history and growth rate from 2017 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
  • CSL net income for the quarter ending June 30, 2021 was $M, a NAN% increase year-over-year.
  • CSL net income for the twelve months ending June 30, 2021 was $0M, a NAN% increase year-over-year.
  • CSL annual net income for 2021 was $2.375B, a 12.96% increase from 2020.
  • CSL annual net income for 2020 was $2.103B, a 9.58% increase from 2019.
  • CSL annual net income for 2019 was $1.919B, a 10.98% increase from 2018.
CSL Annual Net Income
(Millions of US $)
2021 $2,375
2020 $2,103
2019 $1,919
2018 $1,729
2017 $1,337
2016 $1,242
CSL Quarterly Net Income
(Millions of US $)
2021-06-30
2020-12-31
2020-06-30
2019-06-30
2018-06-30
2017-12-31
2017-06-30
2016-06-30
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $101.391B $10.310B
CSL Ltd. is a biopharmaceutical company. It engages in researches, develops, manufactures and markets vaccines and plasma protein biotherapies to treat and prevent human medical conditions. The company's operating segments consists of CSL Behring and bioCSL. CSL Behring segment provides plasma-derived and recombinant products, and operates plasma collection networks through CSL Plasma. bioCSL segment manufactures, sells and distributes vaccines, antivenoms and other pharmaceutical products primarily in Australia and New Zealand; as well as also manufactures and markets in vitro diagnostic products through Immunohaematology. It operates primarily in Germany, Switzerland and the United States. CSL Ltd. is headquartered in Parkville, Australia.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.683B 8.63
Bio-Rad Laboratories (BIO.B) United States $21.975B 46.83
QIAGEN (QGEN) Netherlands $11.773B 19.94
Biohaven Pharmaceutical Holding (BHVN) United States $8.738B 0.00
Emergent Biosolutions (EBS) United States $2.722B 6.57
Arcus Biosciences (RCUS) United States $2.455B 0.00
Myovant Sciences (MYOV) United Kingdom $1.915B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.755B 0.00
Zymeworks (ZYME) Canada $1.208B 0.00
Ambrx Biopharma (AMAM) United States $0.470B 0.00
SQZ Biotechnologies (SQZ) United States $0.342B 0.00
Enzo Biochem (ENZ) United States $0.183B 18.00